Literature DB >> 26306494

Basement Membrane-Based Glucose Sensor Coatings Enhance Continuous Glucose Monitoring in Vivo.

Ulrike Klueh1, Yi Qiao2, Caroline Czajkowski2, Izabela Ludzinska2, Omar Antar2, Donald L Kreutzer2.   

Abstract

BACKGROUND: Implantable glucose sensors demonstrate a rapid decline in function that is likely due to biofouling of the sensor. Previous efforts directed at overcoming this issue has generally focused on the use of synthetic polymer coatings, with little apparent effect in vivo, clearly a novel approach is required. We believe that the key to extending sensor life span in vivo is the development of biocompatible basement membrane (BM) based bio-hydrogels as coatings for glucose sensors.
METHOD: BM based bio-hydrogel sensor coatings were developed using purified BM preparations (ie, Cultrex from Trevigen Inc). Modified Abbott sensors were coated with Cultrex BM extracts. Sensor performance was evaluated for the impact of these coatings in vitro and in vivo in a continuous glucose monitoring (CGM) mouse model. In vivo sensor function was assessed over a 28-day time period expressed as mean absolute relative difference (MARD) values. Tissue reactivity of both Cultrex coated and uncoated glucose sensors was evaluated at 7, 14, 21 and 28 days post-sensor implantation with standard histological techniques.
RESULTS: The data demonstrate that Cultrex-based sensor coatings had no effect on glucose sensor function in vitro. In vivo glucose sensor performance was enhanced following BM coating as determined by MARD analysis, particularly in weeks 2 and 3. In vivo studies also demonstrated that Cultrex coatings significantly decreased sensor-induced tissue reactions at the sensor implantation sites.
CONCLUSION: Basement-membrane-based sensor coatings enhance glucose sensor function in vivo, by minimizing or preventing sensor-induced tissues reactions.
© 2015 Diabetes Technology Society.

Entities:  

Keywords:  Trevigen; basement membrane; biocompatibility; continuous glucose monitoring; extracellular matrices; glucose sensor coatings; implantable glucose sensor

Mesh:

Substances:

Year:  2015        PMID: 26306494      PMCID: PMC4667328          DOI: 10.1177/1932296815598776

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  37 in total

1.  Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering.

Authors:  S E Sakiyama; J C Schense; J A Hubbell
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

2.  Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1).

Authors:  A S Pandit; D J Wilson; D S Feldman
Journal:  J Biomater Appl       Date:  2000-01       Impact factor: 2.646

3.  Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension.

Authors:  J C Schense; J Bloch; P Aebischer; J A Hubbell
Journal:  Nat Biotechnol       Date:  2000-04       Impact factor: 54.908

4.  Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation.

Authors:  A Sahni; C W Francis
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

5.  Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation.

Authors:  A Sahni; C A Baker; L A Sporn; C W Francis
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

6.  Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering.

Authors:  Q Ye; G Zünd; P Benedikt; S Jockenhoevel; S P Hoerstrup; S Sakyama; J A Hubbell; M Turina
Journal:  Eur J Cardiothorac Surg       Date:  2000-05       Impact factor: 4.191

7.  Covalently conjugated VEGF--fibrin matrices for endothelialization.

Authors:  A H Zisch; U Schenk; J C Schense; S E Sakiyama-Elbert; J A Hubbell
Journal:  J Control Release       Date:  2001-05-14       Impact factor: 9.776

8.  Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix.

Authors:  S E Sakiyama-Elbert; J A Hubbell
Journal:  J Control Release       Date:  2000-10-03       Impact factor: 9.776

9.  Cell based metabolic barriers to glucose diffusion: macrophages and continuous glucose monitoring.

Authors:  Ulrike Klueh; Jackman T Frailey; Yi Qiao; Omar Antar; Donald L Kreutzer
Journal:  Biomaterials       Date:  2014-01-22       Impact factor: 12.479

Review 10.  In vitro models of angiogenesis: the use of Matrigel.

Authors:  R Benelli; A Albini
Journal:  Int J Biol Markers       Date:  1999 Oct-Dec       Impact factor: 3.248

View more
  6 in total

1.  Crosslinked basement membrane-based coatings enhance glucose sensor function and continuous glucose monitoring in vivo.

Authors:  Ulrike Klueh; Izabela Ludzinska; Caroline Czajkowski; Yi Qiao; Donald L Kreutzer
Journal:  J Biomed Mater Res A       Date:  2017-09-19       Impact factor: 4.396

Review 2.  Continuous Glucose Monitoring, Future Products, and Update on Worldwide Artificial Pancreas Projects.

Authors:  Jort Kropff; J Hans DeVries
Journal:  Diabetes Technol Ther       Date:  2016-02       Impact factor: 6.118

Review 3.  Future of Automated Insulin Delivery Systems.

Authors:  Jessica R Castle; J Hans DeVries; Boris Kovatchev
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

4.  Impact of CCL2 and CCR2 chemokine/receptor deficiencies on macrophage recruitment and continuous glucose monitoring in vivo.

Authors:  Ulrike Klueh; Caroline Czajkowski; Izabela Ludzinska; Yi Qiao; Jackman Frailey; Donald L Kreutzer
Journal:  Biosens Bioelectron       Date:  2016-06-23       Impact factor: 10.618

Review 5.  Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation.

Authors:  Olesya Didyuk; Nicolas Econom; Angelica Guardia; Kelsey Livingston; Ulrike Klueh
Journal:  J Diabetes Sci Technol       Date:  2020-01-13

Review 6.  Modulating the foreign body response of implants for diabetes treatment.

Authors:  Bhushan N Kharbikar; Gauree S Chendke; Tejal A Desai
Journal:  Adv Drug Deliv Rev       Date:  2021-01-21       Impact factor: 17.873

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.